Literature DB >> 10172794

Health-related quality of life in inflammatory bowel disease.

G M Eisen1, R G Farmer.   

Abstract

Inflammatory bowel disease (IBD) is characterised by a chronic, but frequently remitting, clinical course involving significant morbidity. As medical and surgical advances have occurred, focus has shifted from merely reducing mortality to efforts on decreasing morbidity and improving health status. With this paradigm shift has come the need for qualitative and quantitative assessment of outcomes important to the individual patient. Existing disease activity measures fall short in this area. Health-related quality of life encompasses the areas of physical function, somatic sensation, psychological state and social interactions that are affected by one's health status. Instruments have recently been developed for both generic and disease-specific health states, such as IBD. These psychometric measures have proven to be useful tools for patient assessment. Both medical and surgical trials have incorporated these measures as salient outcomes. An additional outcome that has come under closer scrutiny is the cost of medical interventions. The literature on the cost of IBD is sparse but is likely to increase logarithmically in the future. Quality of life and cost issues are becoming central to the study of not just IBD but all of medicine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10172794     DOI: 10.2165/00019053-199610040-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  35 in total

1.  Outcomes research, cost containment, and the fear of health care rationing.

Authors:  J E Wennberg
Journal:  N Engl J Med       Date:  1990-10-25       Impact factor: 91.245

Review 2.  Review article: assessment of drug therapy in inflammatory bowel disease.

Authors:  H J Hodgson; M Z Mazlam
Journal:  Aliment Pharmacol Ther       Date:  1991-12       Impact factor: 8.171

Review 3.  Quality of life instruments in the evaluation of new drugs.

Authors:  R Jaeschke; G H Guyatt; D Cook
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 4.  Epidemiology of inflammatory bowel disease.

Authors:  B M Calkins; A I Mendeloff
Journal:  Epidemiol Rev       Date:  1986       Impact factor: 6.222

5.  A methodological framework for assessing health indices.

Authors:  B Kirshner; G Guyatt
Journal:  J Chronic Dis       Date:  1985

6.  Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis.

Authors:  J Powell-Tuck; D W Day; N A Buckell; J Wadsworth; J E Lennard-Jones
Journal:  Dig Dis Sci       Date:  1982-06       Impact factor: 3.199

7.  Epidemiology of Crohn's Disease.

Authors:  R S Sandler; A L Golden
Journal:  J Clin Gastroenterol       Date:  1986-04       Impact factor: 3.062

8.  The rating form of IBD patient concerns: a new measure of health status.

Authors:  D A Drossman; J Leserman; Z M Li; C M Mitchell; E A Zagami; D L Patrick
Journal:  Psychosom Med       Date:  1991 Nov-Dec       Impact factor: 4.312

Review 9.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

10.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study.

Authors:  A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.